<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669747</url>
  </required_header>
  <id_info>
    <org_study_id>DCIS-WHM-703M</org_study_id>
    <nct_id>NCT00669747</nct_id>
  </id_info>
  <brief_title>Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)</brief_title>
  <official_title>A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Windy Hill Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Windy Hill Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the safety of 100 mg carboplatin
      administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal
      carcinoma in situ (DCIS) undergoing surgical management 2 to 4 weeks following the Day 15
      intraductal infusion. Secondary objectives are to characterize the biologic and clinical
      effects with respect to: pharmacokinetics, extent of disease on MRI and mammogram,
      histopathological assessment of DCIS, and biomarker measurement of Ki-67, TUNEL and G-actin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, 3-arm, saline-controlled study involving women undergoing surgical
      management of DCIS. Forty-five (45) women who have been diagnosed with DCIS by core biopsy
      will receive intraductal administration of either carboplatin or normal saline (NS) into the
      DCIS-involved breast duct. Thirty (30) patients (i.e., 15 patients per arm) will receive two
      intraductal infusions of either 100 mg of carboplatin or NS on Days 1 and 15. Fifteen (15)
      patients will receive an intraductal infusion of 100 mg carboplatin on Day 1 and an
      intraductal infusion of NS on Day 15. Patients will undergo surgical resection 2 to 4 weeks
      following the Day 15 intraductal infusion (i.e. 4 to 6 weeks from diagnosis).

      The effect of carboplatin on DCIS in the pre-treatment core biopsy specimen and the resection
      specimen will be assessed. Venous blood samples will be collected for carboplatin PK analysis
      pre-dose and at 30 minutes, 1, 2, 4, and 8 hours following intraductal infusions on Days 1
      and 15.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in situ (DCIS) undergoing surgical management 2 to 4 weeks following the Day 15 intraductal infusion</measure>
    <time_frame>2 to 4 weeks following the Day 15 intraductal infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>characterize i.d. carboplatin pharmacokinetics</measure>
    <time_frame>4 -8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>characterize clinical extent of disease on MRI and/or mammogram</measure>
    <time_frame>2 - 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>characterize the histopathological assessment of DCIS</measure>
    <time_frame>4 - 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker measurement of Ki-67, TUNEL and G-actin</measure>
    <time_frame>4 - 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Ductal Carcinoma In Situ</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin infused into DCIS-involved duct on Days 1 &amp; 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin infused into DCIS-involved duct Day 1 and Normal Saline infused into DCIS-involved duct on Day 15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline infused into DCIS-involved duct Days 1 &amp; 15</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin i.d. Days 1 &amp; 15</intervention_name>
    <description>Carboplatin, 10 mg/ml, 10 ml (100 mg) infused into DCIS-involved duct on Days 1 &amp; 15</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin i.d. Day 1; Normal Saline i.d. Day 15</intervention_name>
    <description>Carboplatin 10 mg/ml, 10 ml (100 mg) i.d. DCIS duct on Day 1 Normal Saline, 10 ml i.d. DCIS duct on Day 15</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal Saline, 10 ml, i.d. on Days 1 and 15</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  18 years of age or older

          -  Scheduled to undergo surgical resection in 2 weeks or longer

          -  Pathological diagnosis of DCIS requiring surgical resection

          -  DCIS diagnosed with core biopsy

          -  Mammogram within 6 weeks of diagnosis

          -  Adequate organ function as defined by the following criteria:

        Absolute neutrophil count (ANC) ≥ 1500/μl, Platelets ≥ 140,000/μl,Hemoglobin ≥ 12.0 g/dl,
        Creatinine &lt; 2.0 mg/dl

        - Able to sign informed consent

        Exclusion Criteria:

          -  Current diagnosis of invasive or inflammatory breast carcinoma

          -  DCIS with microinvasion on histology on core needle biopsy

          -  Palpable mass

          -  Mass on mammography

          -  Concurrent anti-cancer therapy

          -  Prior exposure to carboplatin (related to current or past diagnosis)

          -  Prior radiation to the breast or chest wall

          -  Prior areolar or breast surgery which interrupts communication of the ductal systems
             with the nipple

          -  Presence of breast implants

          -  Presence of ulcerating or fungal skin lesions or infection of the breasts

          -  Pregnant or lactating

          -  Impaired cardiac function or history of cardiac problems

          -  Poor nutritional state (as determined by clinician)

          -  Presence of serious infection

          -  Scheduled for intraoperative radiation of breast or chest wall

          -  Allergies to lidocaine or marcaine

          -  Allergies to imaging dyes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Doerr, RN, MSN</last_name>
    <role>Study Director</role>
    <affiliation>Windy Hill Medical, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jane Doerr, RN, MSN</last_name>
    <phone>949-636-4737</phone>
    <email>jdoerr@whmed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andy Dorr, MD</last_name>
    <phone>949-584-4975</phone>
    <email>andy.dorr@whmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>OU Medical Center Laboratory</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William C Dooley, M.D., F.A.C.S.</last_name>
      <phone>405-206-5670</phone>
      <email>William-Dooley@ouhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Linda White, R.N.</last_name>
      <phone>(949) 300-9576</phone>
      <email>lwhite@whmed.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Kuerer, M.D.</last_name>
      <phone>713-745-5043</phone>
      <email>lboehnke@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Linda White, R.N.</last_name>
      <phone>949 300-9576</phone>
      <email>lwhite@whmed.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Love SM, Barsky SH. Anatomy of the nipple and breast ducts revisited. Cancer. 2004 Nov 1;101(9):1947-57.</citation>
    <PMID>15382093</PMID>
  </reference>
  <reference>
    <citation>Li CI, Daling JR, Malone KE. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):1008-11.</citation>
    <PMID>15824180</PMID>
  </reference>
  <reference>
    <citation>Khan SA, Wiley EL, Rodriguez N, Baird C, Ramakrishnan R, Nayar R, Bryk M, Bethke KB, Staradub VL, Wolfman J, Rademaker A, Ljung BM, Morrow M. Ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst. 2004 Oct 20;96(20):1510-7.</citation>
    <PMID>15494601</PMID>
  </reference>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2008</study_first_submitted>
  <study_first_submitted_qc>April 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2008</study_first_posted>
  <last_update_submitted>October 1, 2008</last_update_submitted>
  <last_update_submitted_qc>October 1, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2008</last_update_posted>
  <responsible_party>
    <name_title>Windy Hill Medical, Inc. (Ms. Jane Doerr, R.N., Director of Clinical Development)</name_title>
    <organization>Windy Hill Medical, Inc.</organization>
  </responsible_party>
  <keyword>Ductal Carcinoma In Situ</keyword>
  <keyword>DCIS</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Intraductal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

